SHARP & SLF Annual Scientific Meeting 2022
Thursday, 17 November 2022
King Khalid Auditorium, The Royal College of Surgeons of Edinburgh
Overview
We are delighted to announce the date for the Annual Scientific Meeting which will take place on Thursday 17th November 2022 at the Royal College of Surgeons of Edinburgh. Please join us either in person or virtually for our 34th annual event.
We will be hosting our meeting in the impressive King Khalid Building at the College which was originally St Michael's Church. It boasts a magnificent auditorium with stepped seating and state-of-the-art AV facilities. The King Khalid Building is on Hill Square, directly opposite Ten Hill Place Hotel, where accommodation will be possible alongside your Registration. The downstairs King Khalid Reception Area will house our exhibition, poster display and catering.
Why you should register for this meeting?
Cardiovascular disease, diabetes and all their various clinical manifestations remain one of the most important and frequently seen disease categories in everyday medical practice. Understanding your patients risk of a future cardiovascular event and how we as clinicians can reduce that risk is important to the future well being of our patients.
SHARP Confirmed Keynote Lectures
Professor Roxana Mehran, Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials will be addressing "Reducing the global burden of cardiovascular disease in women: a 20/20 vision for 2030?". Is the risk in women different and do we or should we manage it differently? Find out from Professor Mehran on 17th November.
Professor Sir Rory Collins, Head Of Nuffield Department Of Population Health And BHF Professor Of Medicine And Epidemiology at the University of Oxford will be talking about "Cardiovascular disease prevention: a population-based perspective". Learn from Professor Collins how we should be working to reduce the prevalence of heart attacks and strokes in Scotland.
This year's Scottish Lipid Forum will include a focus on mixed hyperlipidaemia and hypertriglyceridaemia.
SLF Confirmed Speakers
We are delighted to have Professor Anthony Wierzbicki (Guy's & St Thomas', London) joining us to provide an update on approaches to raised triglycerides, and excited to have Professor Deepak Bhatt (Harvard Medical School, Brigham and Women’s Hospital) presenting clinical trial data for Vazkepa.
A full programme will follow shortly.
Sponsors
This event was funded by the companies mentioned through event sponsorship and sponsored sessions for which we are very grateful.
Alnylam
Alnylam is leading the translation of RNA interference (RNAi) into a whole class of innovative medicines with the potential to help patients who have limited or inadequate treatment options live fuller, healthier lives. Founded in 2002 on the bold vision to turn scientific possibility into reality, Alnylam has a robust discovery platform and deep pipeline of investigational medicines, including several programs in late-stage clinical development. Patients are at the core of everything we do; their needs drive our discoveries and their stories further our commitment to delivering innovative therapies.
Amarin UK Limited
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly, committed to reducing cardiovascular risk and making a meaningful impact on patients’ lives.
www.amarincorp.co.uk
Amgen
Astra ZenecaUK Limited
Daiichi Sankyo
www.daiichisankyo.com
Novartis
www.novartis.com
NovoNordisk
www.novonordisk.co.uk
Presentations
SHARP Prize
Prevalence of liver fibrosis biomarkers and associations with all cause mortality in people with type 2 diabetes
C. Curran, A. Collier, M. Hair, L Cameron, S. Wild, C. Byrne
Diabetes Day Centre, NHS Ayrshire and Arran, University Hospital Ayr, Dalmellington Road, Ayr KA6 6DX
Runner Up Oral Presentation
Machine learning to optimise cardiac troponin
for the diagnosis of myocardial infarction
Dimitrios Doudesis, PhD (1, 2), Kuan Ken Lee, MD (1), Jasper Boeddinghaus, MD (1, 3), Anda Bularga, MD (1), Amy V Ferry, PhD (1), Chris Tuck, BSc (1), Matthew TH Lowry, MD (1), Pedro Lopez-Ayala, MD (3), Thomas Nestelberger, MD (3), Luca Koechlin, MD (3, 4), Miguel O Bernabeu, PhD (2, 5), Lis Neubeck, PhD (6) Atul Anand, MD (1), William Parsonage, MD (7), Jaimi H Greenslade, PhD (8-10), Louise Cullen MD (8-10), John W Pickering, PhD (11, 12), Martin P Than, MD (11), Alasdair Gray, MD (13), Christian Mueller, MD (3), Nicholas L Mills, MD (1, 2) on behalf of the CoDE-ACS Investigators
(1) BHF/University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
(2) Usher Institute, University of Edinburgh, Edinburgh, UK
(3) Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Switzerland
(4) Department of Cardiac Surgery, University Hospital Basel, University of Basel, Switzerland
(5) The Bayes Centre, The University of Edinburgh, Edinburgh, UK
(6) School of Health and Social Care, Edinburgh Napier University, Edinburgh
(7) Australian Centre for Health Service Innovation, Centre for Healthcare Transformation, Queensland University of Technology, Brisbane, Queensland, Australia
(8) Emergency and Trauma Centre, Royal Brisbane and Women’s Hospital, Brisbane, Australia
(9) School of Medicine, University of Queensland, Brisbane, Queensland, Australia
(10) Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
(11) Department of Medicine, University of Otago Christchurch, New Zealand
(12) Emergency Department, Christchurch Hospital, New Zealand
(13) Emergency Medicine Research Group Edinburgh, Royal Infirmary of Edinburgh, United Kingdom
Winner Best Poster
Prevalence of ASCVD and treatment patterns stratified by LDL-C in Scotland
Rebecca Wheater (1), Jonathan Malo (2), Jonathan Little (3), Payal Patel (3), Anastasia Lampropoulou (3)
(1) Springfield Medical Center, Arbroath, Scotland
(2) Royal Infirmary Edinburgh, Edinburgh, Scotland
(3) Novartis Pharmaceuticals UK Ltd., London, England
Chronic Kidney Disease: Optimising Pharmacotherapy in Primary Care
Iain Speirits (1), Tania Ramos (2), Amanda Campbell (3), Jane Dely (4)
(1) Advanced Pharmacist Clinical Cardiology, West Glasgow Ambulatory Care Hospital Dalnair Street, Glasgow G3 8SF, United Kingdom
(2) Senior Pharmacist, Primary Care Pharmacy Team, Glasgow City HSCP, Building 2, Templeton Business Centre, 62 Templeton Street, Glasgow G40 1DA, United Kingdom
(3) General Medical Practitioner, Parade Group Practice, Townhead Health Centre, 16 Alexandra Parade, Glasgow G31 2ES, United Kingdom
(4) General Medical Practitioner, Townhead Medical Practice, Townhead Health Centre, 16 Alexandra Parade, Glasgow G31 2ES
Longitudinal profiling of peripheral blood transcriptome and vascular biomarkers to identify patients at risk of major cardiac events following hospitalization for COVID-19
Chloe Hughes, Merete B Long, Holly R Keir, Yan Hui Giam, Thomas Pembridge, Lilia Delgado, Hani Abo Leyah, Rebecca Hull, Amy Gilmour, Diane Cassidy, Hollian Richardson, Amelia Shoemark, Faisel Khan, James D Chalmers
Division of Molecular and Clinical Medicine, University of Dundee, UK
PCSK9 Inhibitors in real-world practice: A single centre prescription data audit
Jacob George (1), Sava Handjiev (2), Prashasthi Devaiah (3)
(1) Department of Clinical Pharmacology, Ninewells Hospital, Dundee
(2) Department of Clinical Biochemistry, Ninewells Hospital, Dundee
(3) University of Dundee School of Medicine, Dundee
Biomarkers for risk straification in chronic coronary syndromes
R. Wereski, PD. Adamson, NS. Shek Daud, FE. Strachan, C. Taggart, A. Bularga, DM. Kimenai, R. Bing, C. Tuck, A. Anand, DJ. Lowe, AR. Chapman, NL. Mills
BHF/University of Edinburgh, Centre for Cardiovascular Science, Chancellor’s Building, 49 Litle France Crescent, Edinburgh, EH16 4SB
